Slingshot Insights | Sunovion Pharmaceuticals Overview

SUNOVION PHARMACEUTICALS Overview

Upcoming Projects (SUNOVION PHARMACEUTICALS)

Don’t see a project related to the company you care about? Create your own!

Upcoming & Overdue Catalysts (SUNOVION PHARMACEUTICALS)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (SUNOVION PHARMACEUTICALS)

Cynapsus plans to submit NDA for APL-130277 to the FDA in the first half of 2017
Tickers: SUNOVION PHARMACEUTICALS, CYNA
Occurred on: Mar 30, 2018
Sunovion Presents Clinical and Health Economics Outcome Research Data for Aptiom (eslicarbazepine acetate) at the American Epilepsy Society (AES) 70th Annual Meeting
Ticker: SUNOVION PHARMACEUTICALS
Occurred on: Nov 28, 2016
Sunovion Announces Publication of Data Evaluating Dose Escalation of Latuda (lurasidone HCl) in the Treatment of Schizophrenia
Ticker: SUNOVION PHARMACEUTICALS
Occurred on: Aug 08, 2016

Strategic Initiatives (SUNOVION PHARMACEUTICALS)

Novartis (NVS) Out-Licenses U.S Rights to Three Treatments for Chronic Obstructive Pulmonary Disease (COPD) to Sunovion Pharmaceuticals
Tickers: NVS, Sunovion Pharmaceuticals
Announcement Date: Dec 21, 2016
Sunovion Pharmaceuticals Acquires Cynapsus Therapeutics for US$40.50 per share in cash
Tickers: CYNA, Sunovion Pharmaceuticals
Announcement Date: Aug 31, 2016